The impact of anti-malarial markets on artemisinin resistance: perspectives from Burkina Faso
- PMID: 37705004
- PMCID: PMC10498571
- DOI: 10.1186/s12936-023-04705-0
The impact of anti-malarial markets on artemisinin resistance: perspectives from Burkina Faso
Abstract
Background: Widespread artemisinin resistance in Africa could be catastrophic when drawing parallels with the failure of chloroquine in the 1970s and 1980s. This article explores the role of anti-malarial market characteristics in the emergence and spread of arteminisin resistance in African countries, drawing on perspectives from Burkina Faso.
Methods: Data were collected through in-depth interviews and focus group discussions. A representative sample of national policy makers, regulators, public and private sector wholesalers, retailers, clinicians, nurses, and community members were purposively sampled. Additional information was also sought via review of policy publications and grey literature on anti-malarial policies and deployment practices in Burkina Faso.
Results: Thirty seven in-depth interviews and 6 focus group discussions were conducted. The study reveals that the current operational mode of anti-malarial drug markets in Burkina Faso promotes arteminisin resistance emergence and spread. The factors are mainly related to the artemisinin-based combination therapy (ACT) supply chain, to ACT quality, ACT prescription monitoring and to ACT access and misuse by patients.
Conclusion: Study findings highlight the urgent requirement to reform current characteristics of the anti-malarial drug market in order to delay the emergence and spread of artemisinin resistance in Burkina Faso. Four recommendations for public policy emerged during data analysis: (1) Address the suboptimal prescription of anti-malarial drugs, (2) Apply laws that prohibit the sale of anti-malarials without prescription, (3) Restrict the availability of street drugs, (4) Sensitize the population on the value of compliance regarding correct acquisition and intake of anti-malarials. Funding systems for anti-malarial drugs in terms of availability and accessibility must also be stabilized.
Keywords: ACT; Antimalarial market; Artemisinin resistance; Burkina Faso; Malaria.
© 2023. BioMed Central Ltd., part of Springer Nature.
Conflict of interest statement
We declare that no competing interests exist.
Similar articles
-
To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?PLoS One. 2021 Aug 31;16(8):e0256567. doi: 10.1371/journal.pone.0256567. eCollection 2021. PLoS One. 2021. PMID: 34464398 Free PMC article.
-
Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders' perspectives in Burkina Faso and Nigeria.PLoS One. 2022 Sep 9;17(9):e0273249. doi: 10.1371/journal.pone.0273249. eCollection 2022. PLoS One. 2022. PMID: 36083995 Free PMC article.
-
Is there evidence of anti-malarial multidrug resistance in Burkina Faso?Malar J. 2021 Jul 19;20(1):320. doi: 10.1186/s12936-021-03845-5. Malar J. 2021. PMID: 34281562 Free PMC article.
-
Patterns of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey and molecular data.Malar J. 2011 May 9;10:116. doi: 10.1186/1475-2875-10-116. Malar J. 2011. PMID: 21554692 Free PMC article.
-
Lessons learnt from 20 years surveillance of malaria drug resistance prior to the policy change in Burkina Faso.Ann Parasitol. 2016;62(1):17-24. doi: 10.17420/ap6201.27. Ann Parasitol. 2016. PMID: 27262953 Review.
Cited by
-
Multiple first-line therapeutic strategies to mitigate artemisinin resistance: cost analysis of a pilot study from a health system perspective in Kaya health district, Burkina Faso.Malar J. 2025 Aug 7;24(1):254. doi: 10.1186/s12936-025-05493-5. Malar J. 2025. PMID: 40775352 Free PMC article.
-
Quest for malaria management using natural remedies.Front Pharmacol. 2024 Jun 26;15:1359890. doi: 10.3389/fphar.2024.1359890. eCollection 2024. Front Pharmacol. 2024. PMID: 39011507 Free PMC article. Review.
References
-
- WHO . World malaria report 2022. Geneva: World Health Organization; 2022.
-
- WHO . Artemisinin resistance and artemisinin-based combination therapy efficacy. Geneva: World Health Organization, Global Malaria programme; 2018.
-
- Achan J, Mwesigwa J, Edwin CP, D’alessandro U. Malaria medicines to address drug resistance and support malaria elimination efforts. Expert Rev Clin Pharmacol. 2018;11:61–70. - PubMed
-
- WHO . Antimalarial drug combination therapy: report of a WHO technical consultation. Geneva: World Health Organization; 2001.
-
- WHO . Guidelines for the treatment of malaria. 3. Geneva: World Health Organization; 2015. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources